CEPI

leads the 100 Days Mission, a coordinated framework to compress the pathogen-to-authorized-vaccine timeline, publishing rapid-response manufacturing frameworks and emergency clinical- research principles with academic and industry partners.

Country: Norway

Government program

Coverage

	CN	EU	US
policy-institutions	✓	✓	✓

Regulatorsfdaema

Verifiable facts

Fact	Value	Source
Affiliation	Coalition for Epidemic Preparedness Innovations (CEPI)	pmc.ncbi.nlm.nih.gov · static.cepi.net
Research focus	100 Days Mission to accelerate vaccine development, rapid-response manufacturing frameworks, and vaccine platforms for epidemic/pandemic pathogens	cepi.net · pmc.ncbi.nlm.nih.gov · static.cepi.net
Facility	Centralised Laboratory Network, Preclinical Model Network, and Vaccine Manufacturing Facility Network	static.cepi.net
Grant	Invests in global R&D and manufacturing partnerships, including vaccine candidates, platforms, and enabling science projects	cepi.net · static.cepi.net
Publications	Strategic reports, annual accounts, board reports, and technical vaccine development/manufacturing frameworks	pmc.ncbi.nlm.nih.gov · static.cepi.net
Principal staff	Richard Hatchett (CEO), Nicole Lurie (Executive Director Emergency Response), and various functional Executive Directors	cepi.net · pmc.ncbi.nlm.nih.gov · static.cepi.net
Headcount	330 employees (as of 31 December 2024)	static.cepi.net

Independent sources: pmc.ncbi.nlm.nih.gov

Technologies

Name	Cluster	Risk
Biological emergency preparedness	policy-institutions	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.